抗凝血治疗败血症临床试验的演变:跨越过去和未来
Toshiaki Iba1,2, Julie Helms3, Cheryl L Maier4
1Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Seminars in thrombosis and hemostasis
|July 29, 2025
概括
治疗败血症的抗凝药疗法在向患有凝血病的患者和使用复合终点 (如分散的血管内凝血 (DIC) 解析) 时表现有希望. 这种方法可以提高临床试验的成功率.
科学领域:
- 关键护理医学 关键护理医学
- 血液学 血液学 血液学
- 临床试验设计 临床试验设计
背景情况:
- 在败血症中证明治疗疗效是具有挑战性的,正如重组激活蛋白C所示.
- 以前对败血症的抗凝血剂试验产生了不一致的结果,可能是由于结果目标和患者选择.
研究的目的:
- 解决败血症临床试验设计的局限性,特别是关于抗凝药疗法.
- 探索改善评估败血症治疗的策略,重点关注患者子组和相关终点.
主要方法:
- 审查历史性败血症试验结果和失败的原因.
- 分析不同结果目标的影响 (例如,28天死亡率与短期措施).
- 检查患者选择 (有DIC的败血症与严重的败血症/败血性休克) 和治疗参数 (时间,剂量,持续时间) 的作用.
主要成果:
- 在使用抗凝剂的败血症试验中观察到不一致的结果,在通过分散的血管内凝血 (DIC) 向败血症方面取得了一些成功.
- 影响试验结果的潜在因素包括不适当的结果目标,患者选择和治疗方案的变化.
- 28天死亡率可能是败血症试验不足的主要终点.
结论:
- 未来的败血症临床试验,特别是那些涉及抗凝剂的临床试验,应该专注于特定的患者群体,如患有凝血病的人群.
- 采用复合终点,例如DIC的解决,对于更准确地评估治疗疗效至关重要.
- 解决试验设计问题对于提高败血症干预的成功率至关重要.
相关概念视频
Clinical Trials
8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.5K
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
911
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
911
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
37
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
37


